Project Grant R21CA297561
Award Date
8/1/25
Completion Date
7/31/27
Dollars Obligated
$405K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
This Project Grant award of $433,125 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports research by the University of Texas Health Science Center at San Antonio to investigate the role of the RNA binding protein SERBP1 in regulating epigenetic processes and gene expression changes relevant to glioblastoma (GBM) development and cell fate. The key research...
The National Cancer Institute (NCI) awarded a $552,968 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to the University of Pittsburgh to conduct research on the role of tRNA modifications in glioblastoma stem cell maintenance and translational reprogramming. The project aims to use mass spectrometry and ribosome profiling to investigate how altered tRNA modifications influence the translational landscape and drive oncogenic processes in glioblastoma, a highly lethal...
This $162,486 Project Grant, awarded by the National Cancer Institute (CFDA Program 93.398 - Cancer Research Manpower), supports research at Case Western Reserve University to study translation regulation and its role in glioblastoma (GBM) stem cell adaptation to hypoxic tumor environments. The research aims to use ribosome profiling and RNA sequencing to elucidate how translational regulation, rather than transcriptional regulation, enables GBM stem cells to survive and proliferate in...
This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $451,996 to the University of Texas at Arlington to develop a high-throughput screening platform for identifying novel therapies to target migrating and treatment-resistant glioblastoma (GBM) cells. The goal is to create an integrated ex vivo system that can reliably induce and screen for drugs that could eradicate or slow down these highly invasive and therapy-resistant brain cancer...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to The University of Texas M.D. Anderson Cancer Center provides $432,134.00 in funding to establish a radiotheranostic approach for treating glioblastoma (GBM), a highly aggressive brain cancer, by targeting the IL13RA2 protein expressed on cancer cells. The research aims to develop human monoclonal antibodies that bind to IL13RA2 with high affinity and specificity, and evaluate the...
This Project Grant award of $1,064,642 from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research at Tufts Medical Center to investigate the role of the angiogenin (ANG) and plexin-B2 (PLXNB2) signaling axis in regulating glioma stem cell (GSC) properties and glioblastoma (GBM) recurrence. The research aims to characterize how the ANG-PLXNB2-tRNA-derived small RNA (tiRNA) pathway maintains GSC stemness and contributes to therapeutic resistance, with the goal...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $609,749 to the University of North Carolina at Chapel Hill to develop a novel combination therapy for the treatment of glioblastoma multiforme (GBM), the most aggressive form of brain cancer. The key products/services to be delivered include: Developing an injectable, biodegradable hydrogel scaffold that can accommodate high concentrations of induced neural stem cells...
The National Cancer Institute (NCI) awarded a $531,550 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to Texas State University to conduct research on discovering novel druggable targets for neuroblastoma differentiation therapy. The research aims to systematically investigate the human druggable genome to identify differentiation-blocking oncogenes in neuroblastoma cells, validate their functions, and evaluate differentiation-inducing activities of inhibitors...
The National Cancer Institute (NCI) awarded a $954,000 Project Grant (CFDA 93.396 - Cancer Biology Research) to the University of Pittsburgh to investigate how aging promotes the growth of glioblastoma, one of the most lethal forms of cancer. The research aims to leverage insights from the biology of neural stem cells and the molecular circuitry of cancer stem cells to understand how aging creates a tumor microenvironment that supports the survival and proliferation of glioblastoma. The...
This federal Project Grant award of $195,000.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research by the Sanford Burnham Prebys Medical Discovery Institute (SBP) to investigate the function and therapeutic potential of R loops in glioblastoma. The research project will be conducted over a 2-year period from August 1, 2025 to July 31, 2027. SBP, a non-profit biomedical research organization, has extensive experience conducting...